SCHEMBL1647808

SCHEMBL1647808

Cc1cccc(-c2[nH]c(Cc3ccc(Cl)cc3Cl)nc2-c2ccc3ncccc3c2)n1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 20/20 0.64
MAPK14 Q16539 9/20 0.62
KDR P35968 2/20 0.62
PRKD1 Q15139 2/20 0.62
PDGFRA P16234 1/20 0.62
FLT1 P17948 1/20 0.62
FLT4 P35916 1/20 0.62
TGFBR2 P37173 1/20 0.52
RIPK2 O43353 1/20 0.51
ACVR1B P36896 1/20 0.51
MTOR P42345 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1649044 0.91 TGFBR1 (0.61) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL3183656 0.89 TGFBR1 (0.71) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1647183 0.88 TGFBR1 (0.75) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1646126 0.83 TGFBR1 (0.66) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1649217 0.83 TGFBR1 (0.66) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1648124 0.83 TGFBR1 (0.66) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1646120 0.83 TGFBR1 (0.69) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1647828 0.83 TGFBR1 (0.65) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL1647245 0.83 TGFBR1 (0.68) TGFBR1MAPK14KDRPRKD1PDGFRA
SCHEMBL3185193 0.82 TGFBR1 (0.69) TGFBR1MAPK14KDRPRKD1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410146-B2 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors SK CHEMICALS CO., LTD. (KR) 2013-04-02 US claimed
US-20100022535-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors SK CHEMICALS CO., LTD. (KR) 2010-01-28 US claimed
US-8410146-B2 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors SK CHEMICALS CO., LTD. (KR) 2013-04-02 US disclosed
US-8410146-B2 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors SK CHEMICALS CO., LTD. (KR) 2013-04-02 US disclosed
US-8410146-B2 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors SK CHEMICALS CO., LTD. (KR) 2013-04-02 US disclosed
EP-2303860-A2 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS SK CHEMICALS CO., LTD. (KR) 2011-04-06 EP disclosed
US-20100022535-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors SK CHEMICALS CO., LTD. (KR) 2010-01-28 US disclosed
US-20100022535-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors SK CHEMICALS CO., LTD. (KR) 2010-01-28 US disclosed
US-20100022535-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors SK CHEMICALS CO., LTD. (KR) 2010-01-28 US disclosed
WO-2009150547-A2 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS SK CHEMICALS CO., LTD (KR) 2009-12-17 WO disclosed
WO-2009150547-A2 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS SK CHEMICALS CO., LTD (KR) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022535-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors ALK, ABL1, ERBB4 TGFBR1 236/4885MAPK14 434/4885KDR 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.